This investment will help BSV avoid carbon dioxide emissions by as much as 6560 tonnes of carbon dioxide equivalent (tCO2e) annually over its project life of 25 years
The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
UNICOR-v has the potential to protect against future epidemics caused by a coronavirus jumping from animals to humans, but also against new variants emerging from SARS-Cov-2
The company will shift 100 percent of its energy use to renewable sources for both power and heat by 2025 in order to achieve carbon neutrality
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants
Increasing syphilis cases, stronger STI surveillance initiatives, and growing emphasis on early diagnosis are expected to support sustained demand
Ariane brings a strong track record within Ardena, including her leadership of the company’s drug product division since 2022
From import dependence to global leadership, the next phase of growth must be driven not only by manufacturing scale and policy support, but also by innovation, research, and globally competitive healthcare technologies
Subscribe To Our Newsletter & Stay Updated
